Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
Total Valuation
Sarepta Therapeutics has a market cap or net worth of $1.75B. The enterprise value is $1.99B.
Market Cap$1.75B
Enterprise Value$1.99B
Share Statistics
Sarepta Therapeutics has 104,989,770 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding104,989,770
Owned by Insiders5.24%
Owned by Institutions4.50%
Financial Efficiency
Sarepta Therapeutics’s return on equity (ROE) is -0.63 and return on invested capital (ROIC) is -29.03%.
Return on Equity (ROE)-0.63
Return on Assets (ROA)-0.21
Return on Invested Capital (ROIC)-29.03%
Return on Capital Employed (ROCE)-0.29
Revenue Per Employee1.60M
Profits Per Employee-519.98K
Employee Count1,372
Asset Turnover0.66
Inventory Turnover0.96
Valuation Ratios
The current PE Ratio of Sarepta Therapeutics is ―. Sarepta Therapeutics’s PEG ratio is 0.00813.
PE Ratio―
PS Ratio1.03
PB Ratio1.98
Price to Fair Value1.98
Price to FCF-7.33
Price to Operating Cash Flow-8.52
PEG Ratio0.00813
Income Statement
In the last 12 months, Sarepta Therapeutics had revenue of 2.20B and earned -713.41M in profits. Earnings per share was -7.13.
Revenue2.20B
Gross Profit1.32B
Operating Income-657.77M
Pretax Income-702.23M
Net Income-713.41M
EBITDA-647.97M
Earnings Per Share (EPS)-7.13
Cash Flow
In the last 12 months, operating cash flow was -205.48M and capital expenditures -111.95M, giving a free cash flow of -317.43M billion.
Operating Cash Flow-205.48M
Free Cash Flow-317.43M
Free Cash Flow per Share-3.02
Dividends & Yields
Sarepta Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.40
52-Week Price Change-83.24%
50-Day Moving Average19.97
200-Day Moving Average21.22
Relative Strength Index (RSI)39.62
Average Volume (3m)2.54M
Important Dates
Sarepta Therapeutics upcoming earnings date is May 6, 2026, After Close (Confirmed).
Last Earnings DateFeb 25, 2026
Next Earnings DateMay 6, 2026
Ex-Dividend Date―
Financial Position
Sarepta Therapeutics as a current ratio of 2.32, with Debt / Equity ratio of 91.14%
Current Ratio2.32
Quick Ratio1.48
Debt to Market Cap0.37
Net Debt to EBITDA-0.37
Interest Coverage Ratio-67.60
Taxes
In the past 12 months, Sarepta Therapeutics has paid 11.19M in taxes.
Income Tax11.19M
Effective Tax Rate-0.02
Enterprise Valuation
Sarepta Therapeutics EV to EBITDA ratio is -3.85, with an EV/FCF ratio of -8.11.
EV to Sales1.13
EV to EBITDA-3.85
EV to Free Cash Flow-8.11
EV to Operating Cash Flow-12.13
Balance Sheet
Sarepta Therapeutics has $939.65M in cash and marketable securities with $1.04B in debt, giving a net cash position of -$99.90M billion.
Cash & Marketable Securities$939.65M
Total Debt$1.04B
Net Cash-$99.90M
Net Cash Per Share-$0.95
Tangible Book Value Per Share$10.61
Margins
Gross margin is 61.34%, with operating margin of -29.92%, and net profit margin of -32.45%.
Gross Margin61.34%
Operating Margin-29.92%
Pretax Margin-31.94%
Net Profit Margin-32.45%
EBITDA Margin-29.48%
EBIT Margin-31.50%
Analyst Forecast
The average price target for Sarepta Therapeutics is $21.06, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$21.06
Price Target Upside26.03% Upside
Analyst ConsensusHold
Analyst Count19
Revenue Growth Forecast47.15%
EPS Growth Forecast-311.26%